Sovilnesib

N/A

Report date: 2023/03/10 15:21:13
NME

Base Information

Drug NameSovilnesib
Drug Alias NameAMG-650
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionKinesin-like protein KIF18A inhibitors
TargetsKinesin-like protein KIF18A
Therapy Area/IndicationsSolid tumoursChromosomal InstabilityFallopian Tube Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[8] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesVolastra Therapeutics IncBeOne Medicines LtdAmgen Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursChromosomal InstabilityFallopian Tube Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A